Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (7243)	12/1/1999 7:33:00 PM
From: tnsaf	Respond to of 9719

INIS is the provider of the isotope for NERX's multiple myeloma therapy that was mentioned by RWR. Friday October 22, 9:00 am Eastern Time Company Press Release SOURCE: International Isotopes Inc International Isotopes Inc Announces Agreement With NeoRx Corporation - Manufacturing Process Line to be Designed for Production of Ho-166 - DENTON, Texas, Oct. 22 /PRNewswire/ -- International Isotopes Inc (Nasdaq: INIS, BSE: ITL) (I3), a commercialization partner for contract manufacturing of finished radiopharmaceuticals and a producer of radioisotopes, pharmaceutical grade radiochemicals and medical devices, today announced that the Company has entered into an agreement with NeoRx Corporation (Nasdaq: NERX - news). Under the agreement, I(3) will design the commercial manufacturing process line for NeoRx's Skeletal Targeted Radiotherapy (STR) product for the treatment of multiple myeloma. STR combines the radionuclide Holmium 166 (Ho-166) with a small molecule that targets bone tissue, resulting in the delivery of high radiation doses to the bone without exposing normal tissues to excessive amounts of radiation. NeoRx is currently conducting clinical trials in patients with diagnosed multiple myeloma to study the effects of combining escalating doses of STR with standard high dose myeloma therapies. NeoRx believes that STR may also be applicable to the treatment of other diseases that arise in, or spread to, the bone marrow such as other blood cancers, prostate and breast cancer. [snip] Full release at biz.yahoo.com NERX will be reporting more interim results of SRT at ASH. According to recap.com this is a P I/II that started this year. Tuesday November 30, 9:00 am Eastern Time Company Press Release SOURCE: NeoRx Corp. NeoRx's Multiple Myeloma Study With Targeted Radiotherapy to be Updated at ASH Recent Thalidomide Results Heighten Interest in New Multiple Myeloma Therapies SEATTLE, Nov. 30 /PRNewswire/ -- NeoRx Corporation (Nasdaq: NERX - news) said further interim data of its Skeletal Targeted Radiotherapy (STR) product in patients with multiple myeloma will be presented by Dr. Richard Champlin, Chairman of the Department of Blood and Bone Marrow Transplantation (MD Anderson Cancer Center, Houston, TX) and one of the principal investigators of the study, at the American Society for Hematology (ASH) meeting in New Orleans on December 7, 1999. Clinical interest in this fatal bone disease and in promising new therapies has been heightened by a recent New England Journal of Medicine article (November 18, 1999, pps. 1565-1571) describing the use of thalidomide for patients who had relapsed after high dose therapy. The ASH presentation on NeoRx's experimental radiation product will report safety data on more than 45 patients and tumor response information on at least 27 of those patients for whom efficacy evaluation is completed. At the International Society of Experimental Hematology meeting (Monaco, July 1999) and the International Multiple Myeloma Workshop (Stockholm, September 1999), the principal investigators reported that 9 of 17 patients had achieved complete response. [snip] Full release at biz.yahoo.com Jason